The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Multidrug resistance: Physiological principles and nanomedical solutions
Open accessAbstract
Multidrug (MDR) resistance is a pathophysiological phenomenon employed by cancer cells which limits the prolonged and effective use of chemotherapeutic agents. MDR is primarily based on the over-expression of drug efflux pumps in the cellular membrane. Prominent examples of such efflux pumps, which belong to the ATP-binding cassette (ABC) superfamily of proteins, are Pgp (P-glycoprotein) and MRP (multidrug resistance-associated protein), nowadays officially known as ABCB1 and ABCC1. Over the years, several strategies have been evaluated to overcome MDR, based not only on the use of low-molecular-weight MDR modulators, but also on the implementation of 1-100(0) nm-sized drug delivery systems. In the present manuscript, after introducing the most important physiological principles of MDR, we summarize prototypic nanomedical strategies to overcome multidrug resistance, including the use of carrier materials with intrinsic anti-MDR properties, the use of nanomedicines to modify the mode of cellular uptake, and the co-formulation of chemotherapeutic drugs together with low- and high-molecular-weight MDR inhibitors within a single drug delivery system. While certain challenges still need to be overcome before such constructs and concepts can be widely applied in the clinic, the insights obtained and the progress made strongly suggest that nanomedicine formulations hold significant potential for improving the treatment of multidrug-resistant malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 1×
“In 1990, for instance, a 95 kDa membrane protein responsible for anthracycline resistance in MCF-7/AdrVp(100) cells was described [5], which later became known as BCRP (Breast Cancer Resistance Protein), and in 1992, Cole and coworkers identified and cloned another phosphoglycoprotein which was highly overexpressed in…”
BackgroundThiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“ABCG2 is furthermore highly expressed in stem cells of different organs, being responsible for a socalled ‘side-population phenotype’, which is marked by a reduced uptake of Hoechst 33342 [40].”
BackgroundSahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Cited by
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Multidrug Resistance: An Emerging Crisis
Tanwar, J., Das, S., Fatima, Z., & Hameed, S. (2014) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2014/541340 · Cited by 657
Formulation of Poloxamers for Drug Delivery
Bodratti, A., & Alexandridis, P. (2018) · Journal of Functional Biomaterials · doi:10.3390/jfb9010011 · Cited by 589
Drug self-delivery systems for cancer therapy
Qin, S.-Y., Zhang, A.-Q., Cheng, S.-X., Rong, L., & Zhang, X.-Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.016 · Cited by 532
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 387
Duan, C., Yu, M., Xu, J., Li, B.-Y., Zhao, Y., & Kankala, R. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114643 · Cited by 335
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Li, B., Shao, H., Gao, L., Li, H., Sheng, H., & Zhu, L. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2094498 · Cited by 289
Zhong, Y., Zhang, J., Cheng, R., Deng, C., Meng, F., Xie, F., & Zhong, Z. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.012 · Cited by 286
Review of Natural Compounds for Potential Skin Cancer Treatment
Chinembiri, T., Du Plessis, L., Gerber, M., Hamman, J., & Du Plessis, J. (2014) · Molecules · doi:10.3390/molecules190811679 · Cited by 270
Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21739 · Cited by 270
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Self-citationPluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Role of Wnt/β‐Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer
Yuan, S., Tao, F., Zhang, X., Zhang, Y., Sun, X., & Wu, D. (2020) · BioMed Research International · doi:10.1155/2020/9390878 · Cited by 131
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery
Jurczyk, M., Jelonek, K., Musiał-Kulik, M., Beberok, A., Wrześniok, D., & Kasperczyk, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030326 · Cited by 133
Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance
Zhang, Y., Zhang, C., Chen, J., Liu, L., Hu, M., Li, J., & Bi, H. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b07219 · Cited by 109
Hu, L., Xiong, C., Wei, G., Yu, Y., Li, S., Xiong, X., Zou, J.-J., & Tian, J. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.10.070 · Cited by 78
Li, X., Yang, X., Lin, Z., Wang, D., Mei, D., He, B., Wang, X., Wang, X., Zhang, Q., & Gao, W. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.04.018 · Cited by 56
Li, Y., Li, R., Liu, Q., Li, W., Zhang, T., Zou, M., Li, H., Wu, T., Cheng, S., Su, Z., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00712 · Cited by 16
Metadata
- Authors
- Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1852-1865
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W1985498995
- Cited by
- 259
- References
- 103
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.